Trial Profile
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Bendamustine; Rituximab
- Indications Mantle-cell lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms SHINE
- Sponsors Janssen Research & Development; Janssen-Cilag
- 27 Feb 2024 Planned End Date changed from 1 May 2024 to 15 May 2024.
- 30 Jan 2024 Planned End Date changed from 15 Dec 2025 to 1 May 2024.
- 15 Nov 2023 This trial has been completed in Belgium and Hungary, according to the European Clinical Trials Database record.